AMPE Stock Price, Ampio Pharmaceuticals Quote, Chart

Market Summary

USD0.35+0.06

Market Closed

20.69%

AMPE Stock Price

View Fullscreen

AMPE RSI Chart

AMPE Valuation

Market Cap

397.4K

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

1.3

EV/EBITDA

0.11

Price/Free Cashflow

-0.05

AMPE Price/Sales (Trailing)

AMPE Profitability

EBT Margin

-10095.69%

Return on Equity

-256.9%

Return on Assets

-150.49%

Free Cashflow Yield

-2.2K%

AMPE Fundamentals

AMPE Revenue

Revenue (TTM)

305.0K

AMPE Earnings

Earnings (TTM)

-8.6M

Earnings Growth (Yr)

7.48%

Earnings Growth (Qtr)

-67.13%

Breaking Down AMPE Revenue

Last 7 days

-53.2%

Last 30 days

-82.6%

Last 90 days

-82.1%

Trailing 12 Months

-92.7%

How does AMPE drawdown profile look like?

AMPE Financial Health

Current Ratio

2.41

AMPE Investor Care

Shares Dilution (1Y)

10.31%

Diluted EPS (TTM)

-10.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.0M	3.2M	0	305.0K
2020	1.8M	8.9M	0	0
2015	85.7K	248.7K	714.7K	1.2M
2014	50.0K	58.9K	67.9K	76.8K
2013	50.0K	50.0K	50.0K	50.0K
2012	26.6K	34.4K	42.2K	50.0K
2011	0	0	0	18.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ampio Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 09, 2023	buchi j kevin	bought	6,284	0.2875	21,858	-
Jun 08, 2023	buchi j kevin	bought	7,400	0.296	25,000	-
May 24, 2023	martino michael a	bought	22,121	0.2877	76,890	ceo
May 16, 2023	buchi j kevin	bought	8,924	0.2743	32,534	-
May 15, 2023	buchi j kevin	bought	10,856	0.2466	44,026	-
May 12, 2023	buchi j kevin	bought	5,513	0.2352	23,440	-
May 12, 2023	stevens david r	bought	9,900	0.22	45,000	-
May 11, 2023	stevens david r	bought	10,875	0.2175	50,000	-
Jan 01, 2022	macaluso michael	sold (taxes)	-38,988	0.57	-68,400	-
Jan 01, 2022	cherevka holli	sold (taxes)	-26,904	0.57	-47,200	president and coo

Which funds bought or sold AMPE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Morton Brown Family Wealth, LLC	unchanged	-	-6.00	6.00	-%
Apr 22, 2024	Kessler Investment Group, LLC	new	-	4.00	4.00	-%
Apr 16, 2024	COUNTRY TRUST BANK	unchanged	-	-8.00	6.00	-%
Apr 15, 2024	Sunbelt Securities, Inc.	unchanged	-	-232	190	-%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	-63.00	52.00	-%
Apr 10, 2024	CVA Family Office, LLC	unchanged	-	-3,558	2,897	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-55.00	72.00	-%
Feb 15, 2024	Farther Finance Advisors, LLC	unchanged	-	-29.00	37.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	366	53.00	86.00	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling AMPE?

Are funds buying AMPE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMPE

No. of Funds

Unveiling Ampio Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 07, 2023	terker bruce e	0%	0	SC 13G/A
Feb 02, 2023	terker bruce e	6.36%	960,150	SC 13G/A
Jul 08, 2022	blackrock inc.	2.1%	4,699,064	SC 13G
Apr 29, 2022	terker bruce e	6.34%	14,402,231	SC 13G/A
Feb 04, 2022	blackrock inc.	6.2%	13,934,805	SC 13G
Jan 20, 2021	terker bruce e	5.96%	11,525,331	SC 13G/A
Jan 23, 2020	empery asset management, lp	1.15%	1,825,029	SC 13G/A
Jan 09, 2020	sabby management, llc	12.%	0	SC 13G/A
Jan 07, 2020	terker bruce e	7.26%	11,525,331	SC 13G/A

Recent SEC filings of Ampio Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	15-12G	15-12G
Apr 04, 2024	25	25
Mar 27, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 04, 2024	EFFECT	EFFECT
Feb 28, 2024	S-8 POS	Employee Benefits Plan
Feb 28, 2024	S-8 POS	Employee Benefits Plan
Feb 28, 2024	RW	RW
Feb 28, 2024	POS AM	POS AM
Feb 28, 2024	8-K	Current Report

Peers (Alternatives to Ampio Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Ampio Pharmaceuticals Inc News

Latest updates

Ampio Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q2	2023Q1	2020Q2	2020Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1
Revenue	-100.0%	-	91,000	3,661,000	7,231,000	682,000	469,213	487,385	184,435	21,429	21,429	21,429	21,429	12,500	12,500	12,500	12,500	12,500	12,500	12,500	12,500	12,500
Operating Expenses	42.0%	2,215,000	1,560,000	4,399,000	2,600,000	6,021,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-20.0%	973,000	1,216,000	3,819,000	1,482,000	1,767,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	261.0%	1,242,000	344,000	524,000	1,118,000	4,254,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-954.0%	-101	-9.65	-5.02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-236,088	-114,425	-	-	5,716	5,547	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,471,762	-7,532,914	-6,193,930	-6,593,259	-4,208,323	-3,677,316	-2,583,968	-2,495,885	-2,835,876
EBT Margin	-936.0%	-100	-9.74	-5.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-49.8%	-2,054,000	-1,371,000	-3,978,000	-2,731,000	-5,179,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-539.7%	-28.30	-4.42	-2.44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	32.1%	-2,309,000	-3,399,000	-2,301,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-25.0%	6.00	8.00	9.00	11.00	14.00	19.00	27.00	33.00	39.00	22.00	27.00	22.00	23.00	16.00	12.00	9.00	14.00	16.00	21.00	13.00	14.00
Current Assets	-25.0%	6.00	8.00	9.00	11.00	13.00	18.00	25.00	30.00	36.00	19.00	23.00	18.00	18.00	11.00	7.00	3.00	8.00	10.00	14.00	6.00	8.00
Cash Equivalents	-36.1%	4.00	6.00	7.00	10.00	13.00	17.00	23.00	29.00	34.00	17.00	21.00	16.00	17.00	9.00	5.00	2.00	7.00	8.00	13.00	5.00	8.00
Net PPE	-	-	-	-	-	0.00	0.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00
Liabilities	4.6%	2.00	2.00	3.00	3.00	2.00	5.00	7.00	11.00	12.00	5.00	6.00	5.00	5.00	5.00	6.00	7.00	8.00	12.00	10.00	13.00	9.00
Current Liabilities	4.6%	2.00	2.00	2.00	3.00	1.00	4.00	5.00	6.00	5.00	2.00	3.00	2.00	2.00	2.00	3.00	4.00	4.00	2.00	2.00	2.00	1.00
Shareholder's Equity	-37.5%	3.00	5.00	7.00	8.00	12.00	14.00	20.00	22.00	27.00	17.00	20.00	17.00	18.00	11.00	6.00	2.00	6.00	4.00	11.00	-	5.00
Retained Earnings	-0.9%	-242	-240	-239	-237	-233	-231	-225	-223	-217	-211	-207	-204	-200	-195	-192	-189	-184	-183	-176	-176	-171
Additional Paid-In Capital	0.0%	246	246	246	246	246	246	245	245	245	229	228	221	218	207	199	192	191	188	187	176	176
Shares Outstanding	3.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	3.00	-	-	-	37.00	-	-	-	330	-	-	-	106	-	-	-	54.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-316.0%	-2,309	-555	-3,399	-2,301	-4,294	-5,943	-5,947	-4,944	-3,704	-3,910	-2,328	-4,147	-2,880	-2,706	-4,590	-4,553	-4,751	-4,738	-3,454	-2,440	-2,326
Share Based Compensation	-11.4%	39.00	44.00	53.00	23.00	669	163	-86.00	716	2,444	47.00	67.00	166	523	477	64.00	213	58.00	246	73.00	28.00	157
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-16.00	-	-81.00	-15.00	-48.00	-	-	-8.00	-	-9.00	-5.00	-78.25
Cashflow From Financing	-	-	-	-	-	-	-	-	-111	20,478	495	7,073	2,686	10,880	7,273	7,017	436	3,247	-	11,085	20.00	1,318

AMPE Income Statement

2023-12-31

Statements of Operations - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Operating expenses

Research and development

$ 2,439,000

$ 8,916,000

General and administrative

7,079,000

11,466,000

Long-lived assets impairment

0

1,614,000

Right of use asset impairment

0

322,000

Loss on sale of fixed assets

56,000

0

Total operating expenses

9,574,000

22,318,000

Other income

Interest income

348,000

220,000

Rental income

305,000

Gain from elimination of ARO obligation, net

289,000

Derivative gain

0

5,761,000

Total other income

942,000

5,981,000

Net loss

$ (8,632,000)

$ (16,337,000)

Net loss per common share:

Basic (in dollars per share)

^[1]

$ (10.66)

$ (21.68)

Diluted (in dollars per share)

^[1]

$ (10.66)

$ (29.32)

Weighted average number of common shares outstanding:

Basic (in shares)

^[1]

810,113

753,615

Diluted (in shares)

^[1]

810,113

753,615

[1]	Net loss per common share and weighted average number of common shares outstanding for the current period have been adjusted and the prior periods have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.

AMPE Balance Sheet

2023-12-31

Balance Sheets - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Current assets

Cash and cash equivalents

$ 4,089,000

$ 12,653,000

Insurance recovery receivable

920,000

0

Prepaid expenses and other

727,000

676,000

Total current assets

5,736,000

13,329,000

Fixed assets, net

0

184,000

Right-of-use asset, net

0

75,000

Total assets

5,736,000

13,588,000

Current liabilities

Accounts payable and accrued expenses

2,102,000

852,000

Lease liability-current portion

274,000

340,000

Total current liabilities

2,376,000

1,192,000

Lease liability-long-term

0

274,000

Warrant derivative liability

0

44,000

Asset retirement obligation

0

289,000

Total liabilities

2,376,000

1,799,000

Commitments and contingencies (Note 6)

Stockholders' equity

Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 833,430 as of December 31, 2023 and 804,674 as of December 31, 2022

0

^[1]

0

Preferred Stock, par value $0.0001; 10,000,000 shares authorized; shares issued and outstanding - none as of December 31, 2023 and December 31, 2022

Additional paid-in capital

245,887,000

245,728,000

Accumulated deficit

(242,527,000)

(233,939,000)

Total stockholders' equity

3,360,000

11,789,000

Total liabilities and stockholders' equity

$ 5,736,000

$ 13,588,000

[1]	December 31, 2023 balances have been adjusted and December 31, 2022 balances have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.

About Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.

CEO	Mr. Michael A. Martino
WEBSITE	https://ampiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Ampio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Ampio Pharmaceuticals Inc? What does AMPE stand for in stocks?

AMPE is the stock ticker symbol of Ampio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ampio Pharmaceuticals Inc (AMPE)?

As of Tue Apr 23 2024, market cap of Ampio Pharmaceuticals Inc is 329.25 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPE stock?

You can check AMPE's fair value in chart for subscribers.

What is the fair value of AMPE stock?

You can check AMPE's fair value in chart for subscribers. The fair value of Ampio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ampio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ampio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPE is over valued or under valued. Whether Ampio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ampio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPE.

What is Ampio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, AMPE's PE ratio (Price to Earnings) is -0.04 and Price to Sales (PS) ratio is 1.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ampio Pharmaceuticals Inc's stock?

In the past 10 years, Ampio Pharmaceuticals Inc has provided -0.58 (multiply by 100 for percentage) rate of return.